Cytokinetics (CYTK) on Monday shared new analyses related to aficamten’s effects associated with standard of care combination therapy and its long-term effects on cardiac structure and function that are expected to be presented at the upcoming Annual American College of Cardiology Scientific Session & Expo 2025, H.C. Wainwright analyst Joseph Pantginis tells investors. The firm thinks the results add to previous profile-building observations supporting aficamten’s potential for cardiac remodeling. H.C. Wainwright reiterates Cytokinetics as a Top Pick and keeps a Buy rating and $120 price target on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics announces presentations as ACC Scientific Session & Expo
- Promising Progress and Positive Outlook for Cytokinetics’ Aficamten in oHCM Treatment
- Cytokinetics regulatory update ‘incrementally positive,’ says Morgan Stanley
- RBC Capital stays bullish on Cytokinetics on lack of AdCom in aficamten view
- Cytokinetics says FDA does not plan advisory committee meeting for aficamten NDA
Questions or Comments about the article? Write to editor@tipranks.com